Clincosm LogoSign in Get a demo

CefiNoFer: Cefiderocol in the Treatment of Multidrug-resistant Gram-negative Bacilli Infections, a Retrospective Study

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT05544682
Collaborator
(none)
15
Enrollment
1
Location
5.6
Anticipated Duration (Months)
2.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Cefiderocol is a new antibiotic from the siderophore cephalosporin family for which there are few real-life data on its use in the treatment of infections with multidrug-resistant Gram-negative bacilli.

The circulation of bacterial strains multi-resistant to antibiotics is important at the Strasbourg University Hospital, so the investigators wish to report their local experience of the 1st uses of Cefiderocol in the treatment of infections with multi-resistant Gram-negative bacilli to antibiotics in order to better clarify the use of this antibiotic (therapeutic indication, method of administration)

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    15 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Cefiderocol in the Treatment of Multidrug-resistant Gram-negative Bacilli Infections, a Retrospective Study
    Actual Study Start Date :
    Sep 1, 2022
    Anticipated Primary Completion Date :
    Feb 17, 2023
    Anticipated Study Completion Date :
    Feb 17, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Clinical Response in Patients Treated as Routine Care with Cefiderocol [Significant clinical improvement at day 30 post treatment]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion criteria:

    • Adult patient (≥18 years old)

    • taken care of in the HUS and treated as part of routine care with Cefiderocol between 04/01/2020 and 08/31/2022.

    • Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.

    Exclusion criteria:
    • Patient who has expressed his opposition to the retrospective reuse of his data for scientific research purposes.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Service des maladies infectieuses et tropicales - CHU de Strasbourg - France Strasbourg France 67091

    Sponsors and Collaborators

    • University Hospital, Strasbourg, France

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Strasbourg, France
    ClinicalTrials.gov Identifier:
    NCT05544682
    Other Study ID Numbers:
    • 8701
    First Posted:
    Sep 16, 2022
    Last Update Posted:
    Sep 16, 2022
    Last Verified:
    Sep 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Strasbourg, France
    Multidrug Resistant Bacterial Infections
    Gram-negative bacilli infections
    Cefiderocol
    Antibiotics
    Additional relevant MeSH terms:
    Infections
    Communicable Diseases
    Bacterial Infections

    Study Results

    No Results Posted as of Sep 16, 2022